Bli medlem
Bli medlem

Du är här

2015-05-26

Ablynx: FMR LLC ANNOUNCE 5.07% SHAREHOLDING IN ABLYNX

REGULATED INFORMATION

GHENT, Belgium, 26 May 2015
-Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announced, in accordance with Article 14 of the Belgian Law of 2 May
2007 regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the "Transparency
Law"), that it received a notification of shareholdings from FMR LLC.

FMR LLC notified that they have increased their shareholding in Ablynx and
have exceeded the 5% threshold. FMR LLC now hold 2,753,606 Ablynx shares,
which represent 5.07% of the current 54,324,572 outstanding shares of Ablynx.

Full versions of all transparency notifications are available on the website
of Ablynx, under the sectionInvestors.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has more than30 proprietary and partnered programmesin development in various
therapeutic areas including inflammation, haematology, immuno-oncology,
oncology and respiratory disease. The Company has collaborations with
multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim,
Eddingpharm, Genzyme, Merck&Co, Inc., Merck Serono and Novartis. The Company
is headquartered in Ghent, Belgium. More information can be found
onwww.ablynx.com.

For more information, please contact Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Ablynx media relations Consilium Strategic Communications:

Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville
t: +44 203 709 5700
e:ablynx@consilium-comms.com

pdf format of the press release
http://hugin.info/137912/R/1923736/689880.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1923736

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.